TEVA-DICLOFENAC SR 75 MG
DICLOFENAC SODIUM : 75 MG · DIN 02158582 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-DICLOFENAC SR?
TEVA-DICLOFENAC SR 75 MG contains DICLOFENAC SODIUM : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02158582, held by TEVA CANADA LIMITED, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Oct-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-DICLOFENAC SR used for?
Symptomatic treatment of rheumatoid arthritis and osteoarthritis, including degenerative joint disease of the hip.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02158582 |
|---|---|
| Brand name | TEVA-DICLOFENAC SR |
| Generic / active ingredient | DICLOFENAC SODIUM : 75 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 75 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB05 DICLOFENAC |
| AHFS class | 08:12.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Oct-2010 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Individualized dose; lowest effective dose for shortest duration. EC: 25-50mg TID/BID. SR: 75-100mg once daily. Max 100mg/day. Take with food/liquid; swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard practice is 15-30°C, but field remains null if not in snippet).
How is it supplied?
EC 25mg: Bottles of 100. EC 50mg: Bottles of 100 and 500. SR 75mg: Bottles of 100. SR 100mg: Bottles of 100.
Contraindications
CABG surgery setting; third trimester of pregnancy; breastfeeding; severe uncontrolled heart failure; hypersensitivity to diclofenac or NSAIDs; active GI ulcer/bleeding; severe renal/hepatic impairment.
Warnings and precautions
Increased risk of serious cardiovascular thrombotic events (MI, stroke); serious gastrointestinal events (bleeding, ulceration, perforation); risk of hypertension and fluid retention.
Is DICLOFENAC in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by PHARMA STULLN INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M01AB05 DICLOFENAC. 15 of 74 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DICLO | 25 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 00839175 |
| APO-DICLO | 50 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 00839183 |
| APO-DICLO SR | 100 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02091194 |
| APO-DICLO SR | 75 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02162814 |
| CAMBIA | 50 MG | POWDER FOR SOLUTION | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 02381680 |
| PMS-DICLOFENAC | 25 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02302616 |
| PMS-DICLOFENAC | 50 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02302624 |
| PRO-DICLOFENAC | 50 MG | TABLET (DELAYED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 00870978 |
| SANDOZ DICLOFENAC RAPIDE | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261774 |
| SANDOZ-DICLOFENAC | 50 MG | SUPPOSITORY | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261928 |
Who else supplies DICLOFENAC worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DICLOFENAC appears in 17208 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.